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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S423in the degeneration of the joint cartilage and pain. The rats showing
pain-related behaviors were selected for the evaluation of TG-C for its
individual cell type (1. hChonJ; 2. hChonJb#7; or 3. TG-C (hChonJ and
hChonJb#7)) for pain and cartilage regeneration. At twoweekspost MIA
administration, the individual cells were injected into the osteoarthritic
knee cavity. The effect of the cells on the mechanical allodynia was
evaluated by von Frey ﬁlament test in blinded fashion. After completing
the test, the knees were harvested for histological analysis.
Results: In MIA model, the reduction of pain was observed in hChonJ#7
treated and TG-C treated groups from day 15 post injection but not in
hChonJ alone or in untreated group. The magnitude of pain reduction in
hChonJ#7 treated group was comparable to that of TG-C treated group
up to day 28. However, TG-C showed longer and greater pain reduction
thereafter up to 8 weeks, indicating synergy between hChonJ and
hChonJ#7 cells. The histological analysis showed that the integrity of
cartilage was severely damaged by MIA treatment. However, hChonJ#7
cell treatment improved the damaged cartilage, in addition, TG-C
treatment showed even greater improvement in the regeneration of the
cartilage.
Conclusions: This study showed that TG-C treatment could reduce pain
and regenerate damaged cartilage in a rat MIA osteoarthritis model and
contributes to the understanding of the effect of TG-C on the
improvement of clinical outcomes observed in phase 2b trials.
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TRADITIONAL CHINESE HERBAL MEDICATED BATH THERAPIES FOR
OSTEOARTHRITIS
B. Chen y, M. Chung z, H. Zhan y, Y. Cao y, C. Wang z. y Shuguang Hosp.
Afﬁliated to Shanghai Univ. of Traditional Chinese Med., Shanghai,
China; z Tufts Med. Ctr., Boston, MA, USATable 1
Effect of traditional Chinese herbal medicated bath therapy on knee osteoarthritis
Author year Na Ageb Bath therapy (formula, water
temperature, dose)c
Control intervention
Li, 2011 204 63 14 Herbs: 9-30g each, 30 min,
twice a day.
Loxoprofen, 60 mg,
3/day
Zhang, 2012 96 58 14 Herbs: 6-15g each, 30 min,
twice a day, Hyaluronate
injection, 2ml/wk
Hyaluronate injectio
12ml/1 wk
Du, 2012 60 63 9 Herbs: 12-15g each, 40-45C,
20-30 min, 2x/day.
Diclofenac topical c
2#/ day.
Chen, 2013 60 57 10 Herbs: 5-30g each, 35-60C,
30 min, 1-2x/day
Diclofenac diethylam
2#/day
Zhang, 2011 90 58 8 Herbs: 5-15g each, 20 min,
once or twice a day
Diclofenac sodium,
75 mg/day
Wu, 2011 98 55 8 Herbs: 20g each, 40 min,
every other day Acupuncture.
Meloxicam, 7.5 mg/
Huang, 2011 120 58 31 Herbs: 9-18g each, 20 min,
twice a day. Oral herbal
medicine
Hyaluronate injecti
12ml/wk
Cheng, 2012 78 53 16 Herbs: 10-30g each, 30 min,
twice a day. Oral herbal
medicine
Meloxicam,
50 mg2/day
Zhang, 2012 60 63 14 Herbs: 10-30g each,
twice a day
Hyaluronate injecti
12ml/wk
Xu, 2013 90 70 13 Herbs: 10-30g each, 40C,
10 min, 3 -4 times/day,
Hyaluronate injection,
12ml/1 wk
Hyaluronate injectio
12ml/1 wk
Wei, 2013 90 62 7 Herbs: 10g each, 30 min, once
a day, Ibuprofen, 1#/day
Ibuprofen, 1#/day
Zhen, 2010 108 60 12 Herbs; 10-30g each, 30 min
twice a day
Diclofenac sodium,
50 mg, 2#/day
a N ¼ number of patients included.
b Age reported in years as a mean.
c Main ingredients:: Lycopodium Clavatum, Garden Balsam Stem, Carthamus Tinctorious,
Zanthoxyli. Additional ingredients: Chinese Starjasmine Stem, Asarum Sieboldii, Erythrin
d Between group comparison.Purpose: Traditional Chinese Herbal Medicated Bath Therapies are
considered to have anti-inﬂammatory effects, activate blood circulation
to remove blood stasis and improve “hemorheologicals” for arthritis. A
comprehensive review of the literature is an important step for
understanding its beneﬁts for knee osteoarthritis (KOA). We system-
atically reviewed the literature on the effects of Herbal Medicated-bath
Therapies in patients with KOA.
Methods: We performed a comprehensive search of three universal
Chinese databases and reference lists of published articles through
November 2013. We included only randomized controlled trials (RCTs)
using herbal medicated bath therapy for adult patients with KOA. The
effect of the Herbal Medicated-Bath Therapy on clinical symptoms was
measured with WOMAC, visual analogue scale, Japanese Orthopedic
Association score, and Lysholm’s score. We accepted the composite
outcome criteria developed by the Chinese National Institute of Rheu-
matology as an endpoint. Study quality was assessed with Jadad criteria
assessing randomization, single blinding, and dropout rates for each
study. The differences between treatment groups were reported as
mean change (P-value).
Results:We identiﬁed 40 potentially relevant studies. Twelve RCTs with
a total of 1154 subjects (62% female) met eligibility criteria. Table 1
summarizes the trials evaluating the effect of Herbal Medicated Bath
Therapies on symptom improvement. Mean age was 60 years and mean
symptom duration was 157 months. All studies were conducted and
published in China between 2010 and 2013, Average bath formula in the
treatment groups included 13 Chinese herbs, vaporing and washing
around the knee with temperature in range 35-600C, 20-40 minutes,
once or twice a day. Mean treatment duration was 3.4 weeks (range 2-
5), for 1-3 courses. All control groups used oral nonsteroidal anti-
inﬂammatory analgesics or intra-articular Hyaluronate injection. Two
studies also used additional oral Chinese herbs. The overall quality ofDuration
(wks)
Outcome
measures
Effect on symptom
(mean or percentage
improvement)d
P value
4 VAS Pain 0.7 Y < 0.05
n, 5 Lysholm''s score 8.4 [ < 0.01
ream, 4 WOMAC pain 0.7Y 0.06
ine, 4 WOMAC pain 5.3 Y < 0.05
2 Lysholm''s score Treatment effect [
87% vs. 67%
< 0.01
day 4 Chinese composite
outcome
Treatment effect [
93% vs. 65%
< 0.05
on, 4 Japanese Orthopaedic
Association criteria
Treatment effect: [
97% vs. 79%
< 0.05
3 Chinese Orthopaedic
Functional Outcome
-1.7
(lower score ¼ better
outcome)
< 0.05
on, 4 Chinese composite
outcome
Treatment effect [
77% vs. 67%
< 0.01
n, 5 Chinese composite
outcome
Treatment effect [
91% vs. 69%
< 0.01
2 Chinese composite
outcome
Treatment effect [
93% vs. 87%
< 0.05
4 Chinese composite
outcome for pain
Treatment effect: [
84% vs. 65%
< 0.05
Processed Radix Aconiti, Kusnezoff Monkshood Root, Radix Clematidis, Pericarpium
a Indicalam, Achyranthes Bidentata, Chinese Quince.
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S424trials was modest (mean Jadad score ¼ 2.08). All studies reported a
positive association between 2 to 5 weeks of Herbal Medicated-Bath
Therapy and improved clinical pain symptoms compared with non-
steroidal anti-inﬂammatory analgesics or hyaluronate injection con-
trols. Mild adverse events were reported in both groups. Discordant trial
designs, lack of reported sufﬁcient qualitative outcome measures and
other methodological limitations precluded a pooled meta-analysis.
Conclusions: These studies suggest that Chinese Herbal Medicated
Bath Therapy may be helpful in the treatment of pain symptoms in
patients with KOA; however, most studies aremodest in quality. Further
rigorously designed and well-controlled RCTs are warranted.Table 1
Lipidomic proﬁles of OA articular cartilage in response to mTOR regulation
m/z peak Lipid assignment Designation Condition
104 Choline [M+H]+ Rapamycin
184 Phosphocholine [M+H]+ Rapamycin
2 Palmitoleamide [M+H]+ Control
285 Stearic acid [M+H]+ Rapamycin
304,2 Arachidonic acid [M+H]+ Control
522,6 Phosphocholine (18:1) [M+H]+ Rapamycin
582,3 Rapamycin Rapamycin
666,4 From m/z Sphingomyelin [M+Na]+ Rapamycin
725,4 Sphingomyelin [M+Na]+ Rapamycin
936,5 Rapamycin [M+Na]+ RapamycinProteomics & Metabolomics
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THE MAMMALIAN TARGET OF RAPAMYCIN REGULATES LIPID
METABOLISM IN OSTEOARTHRITIC HUMAN ARTICULAR CARTILAGE
B. Cillero-Pastor y, P. Lopez de Figueroa z, B. Rocha z,
P. Filgueira-Fernandez z, N. Goyanes z, R.A. Heeren y, F.J. Blanco z,
B. Carames z. y FOM Inst. AMOLF, Amsterdam, Netherlands; zOsteoarticular
and Aging Res. Lab, INIBIC–Complejo Hosp.ario Univ.rio A Coru~na, A
Coru~na, Spain
Purpose: There is increasing evidence indicating that lipid accumu-
lation increases with aging and OA, perhaps contributing to the chon-
drocyte dysfunction. The mammalian target of rapamycin (mTOR) is a
conserved serine-threonine kinase that regulates cell growth, cellular
proliferation and metabolism in response to nutrient signals. In fact, it
has been demonstrated that mTOR mediates in the onset and pro-
gression of diabetes, cancer and ageing process. However, the speciﬁc
involvement of mTOR in the regulation of lipid metabolism in articular
cartilage is poorly understood. The objective of this study is to deter-
mine the effect of mTOR inhibition in the regulation of the lipid
metabolism in human articular cartilage.
Methods: OA cartilage slices were treated with mTORC1 selective
inhibitor Rapamycin (Rapa, 10 mM), mTORC1 and mTORC2 inhibitor
Torin 1 (75 nM), as well as with a limited medium under tissue star-
vation conditions (Hank’s Balance Salt solution, HBSS) for 24 hours. Oil
Red and Nile blue stainings were performed to analyze the effect of
mTOR inhibitors on lipidic species present in OA articular cartilage.
Matrix Assisted Laser Desorption Ionization Mass Spectrometry Imag-
ing (MALDI-MSI) was used to study the differential lipidomic proﬁles
under all conditions. Samples were sectioned in triplicate in 10 mm thick
sections. 2,5-dihydroxybenzoic acid (DHB) matrix at 20 mg/mL in 20
mg/mL MeOH:AcN (50:50) was deposited by a vibrational sprayer
system. A Synapt HDMS MALDI-Q-TOF instrument was used to perform
the imaging-MS and MS/MS experiments with a spatial raster size of
150 mm. Principal Component Analysis (PCA) and Discriminant Analysis
(DA) were used to build regional molecular classiﬁers. Biomap software
was used to visualize molecular distributions. The Lipid Maps database
was used for lipid identiﬁcation.
Results: Lipid histological staining demonstrate that the inhibition of
mTOR dramatically decreases the lipid pool positive staining in OA
articular cartilage, indicating a direct regulation of lipid dynamics by
both pharmacological and physiological regulation of mTOR. However,
the histological analysis was insufﬁcient to detect and identify speciﬁc
lipid species. We employed a MALDI-MSI analysis to extend our
understanding of these processes. PCA and DA revealed different lip-
idomic proﬁles among control, rapamycin, torin and starvation con-
ditions. Firstly, we analyzed the four conditions in a single dataset
where the ﬁrst discriminant function (DF1) clearly separated the
nutrient depleted tissue from the other groups. DF2 predominantly
distinguished between control and rapamycin treated tissue. DA
revealed that Palmitoleamide and Arachidonic acid were increased in
the control condition whereas Phosphocholine and Sphingomyelin
related peaks were speciﬁc from rapamycin condition (Table 1). In
addition, rapamycin fragments were found in the treated samples of
this drug such as m/z 582.3 and m/z 936.5 demonstrating the capability
of the technique to study the lipid metabolism in addition to drug
metabolism in the cartilage.Conclusions: The MSI analysis data indicates that the mTOR regulates
the lipid proﬁle of human OA cartilage. The palmitoleamide and
arachidonic acid, the lipid species identiﬁed on control condition had
been implicated in the aging process and in the regulation of inﬂam-
matory mediators, such as leukotrienes and prostaglandins, respec-
tively. Interestingly, rapamycin treatment modiﬁed the lipid proﬁle to
choline, phosphocholine or sphingomyelin, all implicated to maintain
the cellular membrane integrity. In summary, these results demonstrate
that MALDI-MSI analysis is a useful tool in the study of lipid and ele-
mental composition changes associated with rheumatic pathologies
and exhibit outstanding diagnostic potential.765
QUANTITATIVE PROTEOMIC ANALYSIS REVEALED DIFFERENTIALLY
EXTRACELLULAR PROTEIN PROFILES OF OSTEOARTHRITIC AND
NORMAL MESENCHYMAL STEM CELLS UNDERGOING
CHONDROGENESIS
B. Rocha y, V. Calamia y, V. Casas z, L. Lourido y, C. Fernandez y,
P. Fernandez-Puente y, J. Mateos y, M. Carrascal z, C. Ruiz-Romero y,x,
F.J. Blanco y. yRheumatology Div., Proteomics Group-ProteoRed/ISCIII,
INIBIC-CHUAC, A Coru~na, Spain; z Laboratorio de Proteomica CSIC/UAB,
Barcelona, Spain; xCIBER-BBN, INIBIC-CHUAC, A Coru~na, Spain
Purpose: Chondrogenesis occurs as a result of mesenchymal stem cells
(MSCs) condensation and chondroprogenitor cell differentiation. Fol-
lowing chondrogenesis, the chondrocytes remain as resting cells to
form the articular cartilage. A major challenge for the osteoarthitic (OA)
cartilage reparation by stem cell-based approaches is the under-
standing of this multi-step process. In this work, we have analyzed the
extracellular protein expression proﬁle of human bone marrow MSCs
(hBMSCs) of osteoarthritic patients and control donors undergoing
chondrogenesis, in order to compare the mechanisms involved in the
cartilage extracellular matrix (ECM) remodeling that occurs during the
chondrogenic differentiation process.
Methods: hBMSCs isolated from 3 OA patients and 3 healthy controls
were grownwith different isotope variants of lysine and arginine (Arg6,
Lys4 for the control population and Arg10, Lys8 for the OA population)
during 4-6 weeks, until achievement of full protein labeling. The labeled
populations were then subjected to differentiation in 3D cultures
(micromasses) supplemented with chondrogenic inducers for 14 days.
Proteins in the conditioned media from the two cell populations were
combined, separated by 1D-SDS-PAGE and subjected to in-gel trypsin
digestion using an automatic digestor. The resulting peptide mixtures
were analyzed by nanoLC coupled on-line to an LTQ-Orbitrap XL mass
spectrometer and quantiﬁed using the MaxQuant software and the
Perseus tool.
Results: Real-Time PCR assays showed a relevant difference in the gene
expression of collagen type II in the normal donors when compared to
the OA patients. Moreover, the chondrocyte phenotype was conﬁrmed
in both cases by the proteglycan immunostainings such as aggrecan and
chondroitin-6-sulfate after 14 days in chondrogenesis. Using the pro-
teomic approach, we compared the extracellular protein proﬁles of OA
and normal hBMSC at the same time of differentiation. Among the 531
proteins, 56 had signiﬁcantly altered levels. 35 proteins displayed
consistently higher levels in the OA samples compared to normal
